Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tavilermide
- Development stage
- Phase 3
- Lead developer
- Mimetogen Pharmaceuticals
- Modality
- Small Molecules, Modified Peptides → Peptides
- Administration
- Ophthalmic
01
Overview
Tavilermide is a first-in-class, small-molecule, cyclic tripeptide peptidomimetic that acts as a selective partial agonist of the Tropomyosin receptor kinase A (TrkA) receptor (nerve growth factor receptor). It mimics nerve growth factor (NGF) and activates and potentiates the effects of NGF, which is essential for the health and healing of the ocular surface. Tavilermide is being developed as an ophthalmic solution (eye drop) primarily for the treatment of dry eye disease. The drug facilitates protein secretions from conjunctival glands to help maintain ocular surface lubrication. It was originally synthesized by researchers at Texas A&M University and is under development by Mimetogen Pharmaceuticals. As of June 2024, it has reached phase III clinical trials for dry eye disease in the United States[1][6][7].
- Brand names
- Visonac
- Other names
- tavilermidatavilermidumTAVILERMIDE [INN]263251-78-1
02
Targets
NTRK1 (Tropomyosin-related receptor kinase A)
Beyond the preview
Go deeper on tavilermide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tavilermide.